Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Huons Global Co., Ltd. (084110.KQ)
Seongnam-si, KR
Huons Global Co., Ltd., headquartered in Seongnam, South Korea, is a healthcare enterprise dedicated to delivering a wide array of medical solutions for human well-being, serving both domestic and international markets. The company manufactures and distributes an extensive portfolio of pharmaceutical products. This includes oral solid medications addressing diverse therapeutic areas such as cardiovascular health, metabolic disorders, pain and inflammation, digestive issues, respiratory conditions, infections, urogenital ailments, and general wellness. Their injectable offerings are even more comprehensive, encompassing anesthetics, analgesics, anti-inflammatory agents, muscle relaxants, hormones, enzymes, minerals, antibiotics, and treatments for metabolic, circulatory, and respiratory systems, among many other specialized applications. Beyond pharmaceuticals, Huons Global also provides medical devices, ophthalmic preparations, and biological products. Founded in 1965, the company operated as Huons Co., Ltd. until its rebranding to Huons Global Co., Ltd. in June 2016.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.19% | -16.08% | -50.79% | -50.87% | -43.13% | -38.39% | -35.91% | +51.46% | -53.43% | -38.38% | +206.48% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+4.2% Q1'26: -1.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+11.5% Q1'26: -45.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+2.5% Q1'26: +11.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+10.7% Q1'26: +4.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+6.3% Q1'26: +2.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+3.7% Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.29× Q1'26: 3.43× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-28 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-21 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-18 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-15 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-14 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-13 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-12 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-11 | B+ | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-06 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-29 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-16 | B+ | 3/5 | 2/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex Healthcare 266420.KS | 0.17% | 76.8K | 0.09% |
| 2 | Samsung Kodex Fn Growth ETF 325010.KS | 0.01% | 14.1K | 0.30% |
| 3 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 392.8K | 0.06% |
| 4 | Vanguard FTSE Pacific ETF VPL | 0.00% | 118.7K | 0.07% |
| 5 | Vanguard FTSE Developed Asia Pacific All Cap Index ETF VA.TO | 0.00% | 1.5K | 0.22% |
| 6 | Vanguard FTSE Developed All Cap ex North America Index ETF VIU.TO | 0.00% | 25.1K | 0.23% |
| 7 | Vanguard FTSE Developed All Cap ex North America Index ETF (CAD-hedged) VI.TO | 0.00% | 2.2K | 0.22% |
| 8 | Vanguard FTSE Developed All Cap ex U.S. Index ETF (CAD-hedged) VEF.TO | 0.00% | 2.9K | 0.22% |
| 9 | Vanguard FTSE Developed All Cap ex U.S. Index ETF VDU.TO | 0.00% | 1.9K | 0.22% |
| 10 | Vanguard FTSE Developed Markets ETF VEA | 0.00% | 977.0K | 0.03% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bo-Young Yoon | Vice-Pres and Director | — | male |
| Byeong-Don Choi | Managing Director | — | — |
| Hyeon-Suk Yu | Senior Managing Director | — | — |
| Jeong-Hun Kim | Managing Director | — | — |
| Sangbae Yoon | Vice President & Chief Executive Officer | — | — |
| Sooyoung Song | Pres & Chief Executive Officer | — | — |
| Su-Il Yeom | Managing Director | — | — |
| Yong-Seung Lee | Managing Director | — | male |
| Yun-Bae Kim | Managing Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 084110.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
